ClinicalTrials.Veeva

Menu

Study With Improved Solubility Pazopanib

Netherlands Cancer Institute (NKI) logo

Netherlands Cancer Institute (NKI)

Status and phase

Completed
Early Phase 1

Conditions

Pharmacokinetics of Pazopanib

Treatments

Drug: New Pazopanib formulation

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.

Enrollment

12 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Locally advanced or metastatic cancer;
  • Able and willing to give written consent;
  • WHO performance status of 0, 1 or 2;
  • Able and willing to undergo blood sampling for PK analysis;
  • Minimal acceptable safety laboratory values;
  • Negative pregnancy test for female patients with childbearing potential;
  • Able and willing to swallow oral medication.

Exclusion criteria

  • Any treatment with investigational drugs within 30 days prior to receiving the investigational treatment;
  • Any treatment with CYP3A4, BCRP or PGP interfering drugs;
  • Patients who received treatment with Votrient(R) kess than 1 week ago;
  • Woman who are pregnant or breast feeding;
  • Patients suffering from any known condition that may influence the dissolution or absorption of Pazopanib.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

Treated patients
Experimental group
Treatment:
Drug: New Pazopanib formulation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems